Don't miss out! Create your free JWatch. William J.
By Caroline Helwick July 25, Advertisement. Seidman, MDand colleagues from several cancer centers. These patients are in need of more options that allow them to maintain their quality of life while on treatment.
In fact,breast cancer is the most common cancer among women, except for non-melanoma skin cancer, and women living in North America have the highest rate of breast cancer in the world. Inaboutnew cases of invasive breast cancer will be diagnosed among women in the US, and an estimated 1, cases of breast cancer will be diagnosed in men. Breast cancer is the second leading cause of cancer death in women,exceeded only by lung cancer.
Among the novel chemotherapeutic agents introduced in the last decade, the taxanes have emerged as the most powerful group of compounds, and results available so far confirm that they will be remembered in the future as the breast cancer chemotherapy of the s. Two taxanes are available paclitaxel and docetaxel and they share some characteristics, although they do have some significant differences both in terms of their preclinical profile and, most importantly, their clinical characteristics. There are three main clinical differences: different efficacy-toxicity ratio in relation to dose and schedule; different integrability in anthracycline- and taxane-containing regimens, secondary to differences in pharmacokinetic interactions with anthracyclines; and different level of synergism between each taxane and trastuzumab.
Taxanes are a class of diterpenes. They were originally identified from plants of the genus Taxus yewsand feature a taxadiene core. Paclitaxel Taxol and docetaxel Taxotere are widely used as chemotherapy agents.
Jump to navigation. We reviewed the evidence about the effect of taxane-containing chemotherapy regimens in women with metastatic breast cancer. This is an update of a Cochrane review first published in
Among the novel chemotherapeutic drugs introduced in the s, the taxanes have emerged as the most powerful compounds in breast cancer. Both compounds, paclitaxel and docetaxel, have been evaluated in metastatic settings before adjuvant trials proceeded. Docetaxel was shown in several phase III trials to be superior, particularly in terms of survival, for salvaging polychemotherapies after failure of prior chemotherapy, including that with anthracyclines. A benefit of docetaxel was also reported when compared with doxorubicin after failure of alkylating agents.
Background: Since breast cancer shows diversity in clinical behaviors, a standard therapy does not always lead to favorable outcomes. Materials and Methods: The expression statuses of candidate markers, including topoisomerase-II alpha TOP2Abeta-tubulin B-tuband tissue inhibitor of metalloprotease-1 TIMP-1were immunohistochemically evaluated in 70 breast cancer tissues from 68 patients with advanced breast cancers receiving chemotherapy. Results: The response rates to anthracycline and taxane were Overall,